A Prospective,Open-label, Dose Escalation Phase 1 Study to Investigate the Safety, and Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of a HLX07, in Patients With Advanced Solid Cancers.

Trial Profile

A Prospective,Open-label, Dose Escalation Phase 1 Study to Investigate the Safety, and Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of a HLX07, in Patients With Advanced Solid Cancers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs HLX 07 (Primary) ; Dexamethasone; Diphenhydramine; Ondansetron; Paracetamol
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Shanghai Henlius Biotech
  • Most Recent Events

    • 24 Jan 2017 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.
    • 24 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 15 Aug 2016 Planned End Date changed from 1 Jun 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top